News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/AML-BM-smear-AFIP-190.jpg)
NGS can predict AML relapse after HSCT
- Author:
- HT Staff
Next-generation sequencing (NGS) can be used to predict relapse in acute myeloid leukemia (AML) patients undergoing hematopoietic stem cell...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/scientist_using_a_computer_Credit_Darren_Baker_230.jpg)
Trial sponsors fail to comply with EU rules
- Author:
- HT Staff
Sponsors of clinical trials often do not comply with European Union (EU) rules on reporting results, according to a new study. Researchers looked...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/CLL_cells.jpg)
Stress linked to disease markers in CLL
- Author:
- HT Staff
New research has linked stress levels to markers of progressive disease in patients with chronic lymphocytic leukemia (CLL). Researchers found...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/kymriah-tisagenlecleucel-ctl019-novartis-230.jpg)
NICE rejects DLBCL indication for CAR T-cell therapy
- Author:
- HT Staff
The National Institute for Health and Care Excellence (NICE) has issued a draft guidance saying it cannot recommend tisagenlecleucel (Kymriah) as...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/T-ALL-BM-hind-medyouf-220.jpg)
OBI-3424 receives orphan designation for ALL
- Author:
- HT Staff
The U.S.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/preparing_capsules_for_a_clinical_trial_credit_Esther_Dyson_230.jpg)
ASCO addresses financial barriers to cancer clinical trials
- Author:
- HT Staff
The American Society of Clinical Oncology (ASCO) has issued a policy statement addressing financial barriers to patient participation in cancer...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/vials_drugs_Bill_Branson_230.jpg)
Doc reports ‘very encouraging’ results in penta-refractory MM
- Author:
- HT Staff
HOUSTON—Treatment with selinexor and low-dose dexamethasone can provide a “meaningful clinical benefit” in patients with penta-refractory multiple...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/multiple_myeloma_bone_marrow_aspirate_showing_230.jpg)
CAR T-cell therapy elicits responses in MM
- Author:
- HT Staff
BOSTON—Early results from a phase 1 trial suggest the chimeric antigen receptor (CAR) T-cell therapy P-BCMA-101 can produce responses in patients...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/baby_smiling_Credit_Petr_Kratochvil_230.jpg)
Kids with BCP-ALL exhibit immunological disparities at birth
- Author:
- HT Staff
Patients who develop B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in childhood may have dysregulated immune function at birth,...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/hairy_cell_leukemia-PauloHenriqueOrlandiMourao-220.jpg)
FDA approves drug for hairy cell leukemia
- Author:
- HT Staff
The U.S.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/vonvendi-shire-230.jpg)
EC approves product for von Willebrand disease
- Author:
- HT Staff
The European Commission (EC) has granted marketing authorization for vonicog alfa (Veyvondi), a recombinant von Willebrand factor (rVWF) product...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/MPAL-study-authors-stjude-180.jpg)
Insights could change treatment, classification of MPAL
- Author:
- HT Staff
An extensive analysis of mixed phenotype acute leukemia (MPAL) has led to new insights that may have implications for disease classification and...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/venclexta-month-Abbvie-220.jpg)
MRD data added to venetoclax label
- Author:
- HT Staff
The U.S.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/bhatia-lab-mcmaster-170.jpg)
Cell population appears to drive relapse in AML
- Author:
- HT Staff
Researchers believe they have identified cells that are responsible for relapse of acute myeloid leukemia (AML). These “leukemic-regenerating...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/lab_mouse_closeup_240.jpg)
HIF1A could be therapeutic target for MDS
- Author:
- HT Staff
The transcription factor HIF1A could be a therapeutic target for “a broad spectrum” of patients with myelodysplastic syndromes (MDS), according to...